Company Overview and News

Hazer Group appoints experienced Mineral Resources’ executive to its board

Hazer Group Ltd (ASX:HZR) has appointed Mineral Resources Limited executive Simon Rushton as a non-executive director.
Upvote Downvote

Hazer Group achieves fully continuous operation of the pre-pilot plant

Hazer Group Ltd (ASX:HZR) has reached another milestone by achieving fully continuous operation of its pre-pilot plant for the Hazer Process.
Upvote Downvote

Pocock resigns from Hazer Group

Shares in local tech company Hazer Group have sunk after the company announced on Friday that founder and managing director Geoff Pocock, along with non-executive director Terry Walsh, have both resigned.
Upvote Downvote

Hazer Group’s managing director steps down, leaves company in a strong position

Hazer Group Ltd’s (ASX:HZR) managing director Geoff Pocock has resigned from the company due to personal reasons.
Upvote Downvote

Hazer Group using science technology to create hydrogen and graphite

Hazer Group Ltd (ASX:HZR) aims to commercialise its low cost, low emission process to produce hydrogen and graphite known as the Hazer Process.
Upvote Downvote

Hazer Group technology could position it to enter global industrial hydrogen market

Hazer Group Ltd (ASX:HZR) has completed preliminary process modelling and commodity cost analysis of its Hazer Process, a lower emission hydrogen graphite production process.
Upvote Downvote

Hazer Group enters 2018 cashed up, more inflows expected

Hazer Group Ltd (ASX:HZR) has entered the 2018 calendar year with cash reserves of $8.32 million, an increase of $1.6 million on the prior quarter.
Upvote Downvote

Hazer Group’s Geoff Pocock exercises in-the-money options

Hazer Group Ltd (ASX:HZR) managing director Geoff Pocock has demonstrated his confidence in the company by increasing his stake with the exercise of 3 million options.
Upvote Downvote

Hazer and MinRes to build plant

Tech company Hazer Group has signed a binding agreement with Mineral Resources to develop a facility to produce synthetic graphite.
Upvote Downvote

Hazer Group teams with Mineral Resources to build synthetic graphite facilities

Hazer Group Ltd (ASX:HZR) and Mineral Resources Ltd (ASX:MIN) has executed a binding agreement for the design and construction of commercial scale synthetic graphite facilities.
Upvote Downvote

Hazer Group takes another step to advance pre-pilot plant

Hazer Group Ltd (ASX:HZR) has taken a significant step towards de-risking the scale-up of its Hazer Process technology.
Upvote Downvote

Hazer Group receives interest from steel industry for its technology

Hazer Group (ASX:HZR) has signed a memorandum of understanding (MoU) to investigate the commercial and technical viability of utilising the Hazer technology in the steel industry.
Upvote Downvote

MinRes makes bid for Hazer clean fuel synthetic graphite tech

Mineral Resources, owners of the Mt Marion lithium project in Kalgoorie, has made a deal with Perth-based company Hazer Group to create a facility for large-scale, high-grade synthetic graphite production.
Upvote Downvote

Hazer to build plant with MinRes

Tech company Hazer Group has entered into a collaboration agreement with diversified business Mineral Resources, for development of a facility to produce synthetic graphite.
Upvote Downvote

Hazer Group shares soar on potential commercial facility

Hazer Group (ASX:HZR) has signed a non-binding heads of agreement with Mineral Resources Limited (ASX:MIN) to jointly develop a large-scale commercial synthetic graphite facility.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...